Drugs

Exam Prep

Glossary

Handouts

SchoolsNew

Contact Lenses Medications Glossary Calculators Handouts Exam Prep

Disclaimer Privacy Policy Terms of Use Contact

Educational resource only — not medical advice. Independent study tool, not affiliated with or endorsed by the NBEO®. See our Disclaimer.

Medications›Injections & Implants›Avastin

Avastin®

GoodRx

Bevacizumab · injectable solution

Injections & Implants

OFF-LABELNot in the FDA label for this product

Neovascular (wet) age-related macular degeneration

1.25 mg in 0.05 mL by intravitreal injection, typically monthly or as needed on OCT and acuity review

RCT, n=1185

The CATT trial randomised patients with neovascular AMD to bevacizumab or ranibizumab, monthly or as-needed. At two years bevacizumab and ranibizumab produced equivalent effects on visual acuity when given on the same schedule, and as-needed dosing produced less gain than monthly dosing for both drugs.

Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-year Results. Ophthalmology. 2012

Diabetic macular edema and macular edema following retinal vein occlusion

1.25 mg in 0.05 mL by intravitreal injection, repeated on OCT and acuity review

RCT, n=660

Protocol T compared aflibercept, bevacizumab and ranibizumab for centre-involved diabetic macular oedema. At one year all three improved vision; aflibercept was more effective than bevacizumab where baseline acuity was 20/50 or worse, and the three were comparable where baseline acuity was better than that.

Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. New England Journal of Medicine. 2015

Contraindications

Other Injections & Implants drugs

Actemra®
Beovu®
Botox®
Dextenza®
Durysta®
Eylea®
Fluorescite®
Fluorouracil

Browse all medications All Injections & Implants drugs

None.

Available Forms

Injection, supplied for intravenous oncology use as 100 mg/4 mL and 400 mg/16 mL single-dose vials. Ophthalmic use requires compounding into single-use syringes by a compounding pharmacy.

Mechanism of Action

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors Flt-1 and KDR on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation.

Warnings & Precautions

Compounding: the ophthalmic product does not come from the manufacturer. Clusters of endophthalmitis have been traced to compounding failures, so the pharmacy matters as much as the technique.
Intravitreal injection carries a risk of endophthalmitis, retinal detachment and raised intraocular pressure.
The intravenous label carries boxed-level warnings for gastrointestinal perforation, wound healing complications and severe haemorrhage; these belong to systemic dosing, which is orders of magnitude above the intravitreal dose.
Arterial thromboembolic events have been reported after intravitreal VEGF inhibition, though causality is unsettled.

Common Side Effects

Ocular, after intravitreal injection: conjunctival haemorrhage, eye pain, floaters and raised intraocular pressure, with endophthalmitis and retinal detachment as rare but serious events. Systemic, from the oncologic intravenous use: hypertension, proteinuria, epistaxis, headache and impaired wound healing.

Pregnancy & Lactation

Pregnancy: Avastin may cause fetal harm in pregnant women. Limited postmarketing reports describe cases of fetal malformations with use of Avastin in pregnancy.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Intravitreal bevacizumab has been used off-label in retinopathy of prematurity, where systemic VEGF suppression and its effect on developing organs remain a subject of study.

Avastin (Bevacizumab) | EyeKnow O.D.